OFI Invest Asset Management Has $95.58 Million Stake in Eli Lilly and Company $LLY

OFI Invest Asset Management decreased its position in Eli Lilly and Company (NYSE:LLY) by 5.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,617 shares of the company’s stock after selling 7,286 shares during the period. OFI Invest Asset Management’s holdings in Eli Lilly and Company were worth $95,584,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Ackerman Capital Advisors LLC lifted its holdings in Eli Lilly and Company by 5.8% in the second quarter. Ackerman Capital Advisors LLC now owns 272 shares of the company’s stock valued at $212,000 after buying an additional 15 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new position in Eli Lilly and Company in the second quarter valued at $40,217,000. Means Investment CO. Inc. lifted its holdings in Eli Lilly and Company by 4.0% in the second quarter. Means Investment CO. Inc. now owns 5,021 shares of the company’s stock valued at $3,914,000 after buying an additional 194 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in Eli Lilly and Company by 11.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 121,020 shares of the company’s stock valued at $94,420,000 after buying an additional 12,674 shares during the period. Finally, Oak Ridge Investments LLC lifted its holdings in Eli Lilly and Company by 1.4% in the second quarter. Oak Ridge Investments LLC now owns 59,415 shares of the company’s stock valued at $46,316,000 after buying an additional 802 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 2.6%

LLY opened at $833.08 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a market capitalization of $788.47 billion, a PE ratio of 54.45, a P/E/G ratio of 1.16 and a beta of 0.47. The company’s 50-day moving average is $742.42 and its 200 day moving average is $765.94.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business posted $3.92 EPS. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of several research reports. Berenberg Bank reiterated a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley dropped their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.